The Scalpel's Edge

Dr. Tim Sayed
  • 5.0 (5)
  • Medicine
  • Updated Bimonthly

The Scalpel's Edge is a podcast hosted by Dr. Tim Sayed, a leading plastic surgeon and physician innovator, dedicated to exploring the forefront of excellence and wellness. The show delves into cutting-edge medical technologies, industry controversies, and innovative approaches to healthcare and personal growth. With insightful discussions featuring top leaders and innovators from healthcare and beyond, the podcast aims to optimize performance, enhance wellness, and deepen self-understanding. Listeners can follow the podcast on platforms like Apple and Spotify to join this journey into groundbreaking advancements and out-of-the-box thinking.

  1. 5d ago

    Ep. 39 - GLP-1 Prescriptions Without Obesity or Diabetes

    Dr. Tim Sayed examines GLP-1 prescriptions for people without obesity, diabetes, or another apparent FDA-approved indication, looking at new research on how medications such as semaglutide and tirzepatide are increasingly being used beyond their established indications. A large study of U.S. medical records found prescribing without an apparent approved indication increased 15-fold between 2021 and 2025, with more than one-third of these patients having a normal BMI. The numbers open a more complicated conversation about off-label prescribing, compounded GLP-1 medications, telehealth access, cost, and why patients may seek these drugs for potential benefits that are still being studied. Dr. Sayed also considers a concerning finding around eating disorders and emphasizes the responsibility of prescribers to distinguish thoughtful off-label care from simply providing a medication because someone wants it. The research has important limitations, including that a missing diagnosis in an electronic health record does not necessarily mean a patient never qualified for treatment. For Dr. Sayed, that nuance matters. GLP-1 medications have become a cultural phenomenon, but expanding access also raises questions about evidence, appropriate prescribing, patient monitoring, and how these drugs should be used as their potential applications continue to evolve. Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com Website: timsayedmd.com Instagram: @timsayedmd YouTube: @Timsayedmd Facebook: Tim Sayed MD

  2. Aug 25

    Ep. 38 - Breast Implant Removal and New Options for Restoring Breast Volume

    Dr. Tim Sayed looks at breast implant removal, breast implant illness, and the challenge of restoring breast volume after explant surgery, especially for women who have little natural breast tissue or not enough body fat for traditional fat transfer. He explains why removing an implant does not simply return the breast to its pre-augmentation appearance and why concerns about shape and volume can become an important part of the explant conversation. The discussion moves through current and emerging options, including fat transfer and AlloClae, a processed donor fat product that Dr. Sayed says may offer modest volume and contour correction without requiring additional liposuction. He also examines an investigational 3D-printed, absorbable breast scaffold being studied in Australia. The scaffold is designed to provide implant-like structure while being seeded with the patient's own fat and eventually absorbing as the patient's tissue remodels. Early trial results discussed in the episode are promising, but Dr. Sayed emphasizes that the technology is still being evaluated and should undergo rigorous scientific and clinical testing before broader use. For patients considering explant surgery, these developing technologies could eventually expand the choices available for restoring breast shape without returning to a permanent breast implant, but the research is still unfolding. Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com Website: timsayedmd.com Instagram: @timsayedmd YouTube: @Timsayedmd Facebook: Tim Sayed MD

  3. Aug 11

    Ep. 37 - Retatrutide Weight Loss Risks and Why the Black Market Isn't Worth It

    Dr. Tim Sayed continues his conversation about retatrutide, the investigational GLP-1 medication drawing widespread attention for weight loss, by looking beyond the clinical results and focusing on the growing black market surrounding the drug. He examines how people are obtaining products advertised through encrypted messaging platforms, overseas suppliers, and online marketplaces despite retatrutide not being FDA approved or legally available for prescribing. Drawing from recent reporting and reader responses, Dr. Sayed reflects on the questions patients are asking about affordability, access, compounded GLP-1 medications, and the balance between innovation and safety. He explains why physician-supervised prescribing through licensed providers and regulated compounding pharmacies is fundamentally different from purchasing products marketed for research purposes with no clear chain of accountability. The conversation also explores concerns about product quality, third-party testing, reported adverse events, and the practical realities of navigating today's rapidly evolving weight loss landscape. As the discussion comes to a close, Dr. Sayed broadens the conversation to the larger idea behind The Scalpel's Edge, reflecting on optimizing performance in health, family, business, and everyday life. Inspired by attending the FIFA World Cup, he connects the themes of discipline, resilience, and shared human experience with his ongoing mission to help patients pursue lasting wellness through thoughtful, informed decisions rather than shortcuts. Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com Website: timsayedmd.com Instagram: @timsayedmd YouTube: @Timsayedmd Facebook: Tim Sayed MD

  4. Jul 28

    Ep. 36 - Retatrutide Weight Loss Drug and the Risks of the Black Market

    Dr. Tim Sayed explores retatrutide, the investigational GLP-1 medication generating significant attention for medically supervised weight loss, and explains why its early clinical trial results have created so much excitement. He walks through the Phase 3 obesity data released by Eli Lilly, comparing reported weight loss outcomes with existing GLP-1 medications while explaining how retatrutide's triple agonist mechanism differs from earlier treatments. As the conversation unfolds, the focus shifts to a growing concern: despite not being FDA approved or legally available for prescribing anywhere in the world, retatrutide is already being purchased through online marketplaces, encrypted messaging apps, and overseas suppliers. Dr. Sayed reflects on recent reporting about this emerging black market, discussing the uncertainty surrounding product quality, contamination risks, and the challenges of obtaining medications outside established medical channels. He also distinguishes physician-supervised compounded GLP-1 treatment from unregulated products marketed for "research purposes" and explains why he views those situations very differently. Rather than dismissing the promise of new weight loss medications, Dr. Sayed balances genuine optimism about future therapies with caution about how patients access them. His takeaway is simple: remarkable clinical results do not eliminate the importance of safety, oversight, and thoughtful medical care. Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com Website: timsayedmd.com Instagram: @timsayedmd YouTube: @Timsayedmd Facebook: Tim Sayed MD

  5. Jun 9

    Ep. 35 - GLP-1 Medications and Breast Cancer Risk: Breaking Down a Landmark New Study

    Dr. Tim Sayed walks through a recently accepted study from the Journal of Clinical Oncology Practice showing that GLP-1 medications like Ozempic, Mounjaro, and Zepbound are associated with a significant reduction in breast cancer incidence in overweight women. The paper, led by researchers at the University of Pennsylvania, analyzed electronic health records from roughly 111,000 women ages 45 to 80 with a BMI over 25, comparing breast cancer outcomes between those who had GLP-1 prescriptions and those who did not. The reduction in incidence held across age, race, ethnicity, BMI, breast density, and diabetes status. Dr. Sayed is careful to note what the study is and isn't: it's a retrospective observational cohort, not a randomized controlled trial, and the authors themselves say prospective trials are the necessary next step. He examines the proposed biological mechanisms, how GLP-1 drugs may inhibit cancer cell proliferation and reduce systemic inflammation, and draws a comparison to tamoxifen's established but side-effect-heavy role in breast cancer prevention. He also raises open questions about duration of use, what happens when patients stop, affordability at a population level, and whether pharmaceutical companies have the incentive to pursue formal cancer prevention trials. For patients already navigating GLP-1 treatment or breast health decisions, the findings are worth understanding clearly, even before the full picture is in. Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com Website: timsayedmd.com Instagram: @timsayedmd YouTube: @Timsayedmd Facebook: Tim Sayed MD Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com Website: timsayedmd.com Instagram: @timsayedmd YouTube: @Timsayedmd Facebook: Tim Sayed MD

  6. Jun 2

    Ep. 34 - Food Noise, GLP-1 Medications, and the Set Point: Why Weight Comes Back

    Dr. Tim Sayed walks through a recent New York Times article on food noise — the persistent mental chatter about eating that many people with obesity describe as relentless — and what GLP-1 medications like semaglutide and tirzepatide appear to do to quiet it. Drawing on both his clinical experience prescribing these medications and his own personal use of them, Sayed unpacks the concept of the set point: the weight a body seems to naturally gravitate toward, which researchers believe may be dysregulated in obesity. The piece raises a question Sayed finds genuinely unresolved — if GLP-1s are suppressing food noise by resetting the set point, what exactly is being reset, and where in the brain is that happening? Patient accounts from the article illustrate how dramatic the shift can feel — and how quickly food noise returns when the medications stop. Sayed doesn't frame this as a failure of the drugs. He's more interested in what it reveals about the underlying biology, and whether behavioral changes adopted during treatment can outlast the medication itself. He also touches on the broader compulsion research emerging around GLP-1s — gambling, alcohol, smoking — and what it might mean that a single drug class appears to quiet such different urges. The honest takeaway here isn't a clean answer but a more precise version of the question: the drugs work, the biology is real, and the mechanisms still aren't fully understood. Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com Website: timsayedmd.com Instagram: @timsayedmd YouTube: @Timsayedmd Facebook: Tim Sayed MD Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com Website: timsayedmd.com Instagram: @timsayedmd YouTube: @Timsayedmd Facebook: Tim Sayed MD

  7. May 19

    Ep. 33 - GLP-1 Side Effects Patients Are Actually Reporting and What Reddit Data Reveals

    Dr. Tim Sayed walks through an April 2026 study published in Nature that analyzed over 410,000 Reddit posts from people using semaglutide and tirzepatide, using AI language models to extract and categorize what patients were actually saying about their experiences on these medications. The study identified roughly 67,000 self-reporting users, and among them, 43.5% described at least one side effect, with nausea leading at 37%, followed by fatigue, vomiting, constipation, and diarrhea. What makes this study notable, and what Sayed spends real time on, is where the real-world data diverges from the clinical trial record. Fatigue appeared far more commonly in Reddit posts than in formal trial reporting. Reproductive symptoms including irregular periods, mid-cycle bleeding, and heavy cycles emerged as a signal in about 4% of users reporting any side effect, something not well captured in current drug labeling. Temperature-related complaints like chills and hot flashes showed up as well, which the study authors connected speculatively to glucagon's known role in thermogenesis. Sayed is careful to carry the study's own caveats: selection bias is real, Reddit skews younger and American, and voluntary self-reporting cannot establish true prevalence. The broader point he lands on is practical. Prescribers should know what patients are reading and talking about, because those conversations are already shaping what people expect and ask about in the clinic. Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com Website: timsayedmd.com Instagram: @timsayedmd YouTube: @Timsayedmd Facebook: Tim Sayed MD Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com Website: timsayedmd.com Instagram: @timsayedmd YouTube: @Timsayedmd Facebook: Tim Sayed MD

  8. May 5

    Ep. 32 - Breast Implant Illness and Explant Surgery: One Patient's Journey Through Symptoms, Revisions, and Recovery

    Dr. Tim Sayed speaks with Rachel Blogg, a licensed psychotherapist and athlete who spent roughly three and a half years navigating breast augmentation, multiple revisions, capsular contracture, implant malposition, and eventually explant surgery before finding relief from symptoms she hadn't initially connected to her implants at all. Rachel's account moves through the full arc — from her original decision to augment after breastfeeding two children, to a series of escalating complications including bottoming out, repeated capsular contracture, and an unsanctioned implant exchange that left her significantly asymmetric and heavier, unable to exercise, and experiencing joint pain severe enough that she underwent four separate trigger finger surgeries that, in retrospect, may never have been necessary. Dr. Sayed contextualizes what Rachel experienced — biofilm theory, the mechanics of under-muscle placement and restricted breathing, and why complete capsulectomy matters in explant surgery — while being careful not to overstate what the evidence currently supports about breast implant illness. Rachel describes symptom resolution that began in the recovery room and continued over the following years: finger pain gone, hair regrowing, thyroid levels stabilizing, and twenty-two pounds lost without changing her approach to diet or training. The conversation turns honestly toward the psychological dimension — radical acceptance as a clinical concept, body image work, the role of a supportive partner, and why Rachel, a DBT therapist herself, waited a full year before pursuing her final surgery. The episode doesn't resolve the broader debate around BII, but it doesn't need to. What it offers is one carefully observed account of what recovery from implants can actually look like. Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com Website: timsayedmd.com Instagram: @timsayedmd YouTube: @Timsayedmd Facebook: Tim Sayed MD Contact Dr. Tim Sayed: Phone: (858) 247-2933 Email: info@timsayedmd.com Website: timsayedmd.com Instagram: @timsayedmd YouTube: @Timsayedmd Facebook: Tim Sayed MD

See All (40)

5
out of 5
5 Ratings

About

The Scalpel's Edge is a podcast hosted by Dr. Tim Sayed, a leading plastic surgeon and physician innovator, dedicated to exploring the forefront of excellence and wellness. The show delves into cutting-edge medical technologies, industry controversies, and innovative approaches to healthcare and personal growth. With insightful discussions featuring top leaders and innovators from healthcare and beyond, the podcast aims to optimize performance, enhance wellness, and deepen self-understanding. Listeners can follow the podcast on platforms like Apple and Spotify to join this journey into groundbreaking advancements and out-of-the-box thinking.

Information

  • Creator
    Dr. Tim Sayed
  • Years Active
    2025 - 2026
  • Episodes
    40
  • Rating
    Clean
  • Copyright
    © 2026 The Scalpel's Edge
  • Show Website
    The Scalpel's Edge